Pharmacokinetics and safety profile of desmopressin oral tablet formulations in healthy Chinese subjects under fasting and fed conditions

What Was Tested

Researchers studied Vasopressin and Desmopressin in this clinical study publication.

Desmopressin acetate (DDAVP®) is a synthetic analogue of the pituitary hormone vasopressin.

This study aimed to assess the effect of food intake on the PK of desmopressin and bioequivalence of two tablet formulations in Chinese subjects.

Who Took Part

The study group was 104 volunteers.

PubMed indexes the participants as teenagers, young adults and adults, both men and women.

How the Study Was Run

In design terms this was a randomized, open-label and crossover study.

The volunteers were allocated by chance, so the Vasopressin group and the comparison group should start out alike.

Being open-label, the Vasopressin study did not mask who received what.

In the crossover set-up each of the volunteers took both Vasopressin and the comparison in turn, acting as their own control.

Plasma desmopressin concentrations were analyzed by validated liquid chromatography-tandem mass spectrometry (LC-MS/MS).

PK and bioavailability parameters were calculated.

Adverse events (AEs) were also recorded.

What Was Measured

Topics PubMed links to this paper include Antidiuretic Agents, Area Under Curve, Asian People, Biological Availability, China, Chromatography, High Pressure Liquid and Deamino Arginine Vasopressin.

What This Means in Plain Language

The paper is a randomized, open-label and crossover study of Vasopressin and Desmopressin in 104 volunteers.

Its findings take up roughly 5 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2018 (International journal of clinical pharmacology and therapeutics), a journal based in Germany.

More context: the Vasopressin compound page and the Desmopressin compound page, all human trials.